Pregabalin Capsule
Product Images NDC 72162-1544

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1544). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621544)

Label for Pregabalin Capsules 100 mg, oral dosage form. The label indicates a package of 90 capsules, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by ScieGen Pharmaceuticals Inc. It includes storage instructions at 20°-25°C and a warning to keep out of reach of children. The label features a barcode, NDC 72162-1544, and a QR code.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin and placebo. Four lines represent Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating their comparative pain improvement profiles.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing percent of patients improved versus percent improvement in pain from baseline. Two curves represent Pregabalin 100 mg taken three times a day and placebo, showing higher patient improvement percentages with Pregabalin across the range.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting percent of patients improved by percent improvement in pain from baseline for different Pregabalin dosages (300 mg, 150 mg, 75 mg, twice a day) and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows percent of patients improved from 0 to 100%.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The lines indicate that higher doses of Pregabalin correspond to higher percentages of patient improvement relative to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart showing the percent of patients improved based on the percent improvement in pain from baseline. Three lines represent Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating relative efficacy across different levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (percentage) in two clinical studies, Study E1 and Study E3. The x-axis shows treatment groups including placebo and various daily doses of pregabalin (e.g., 50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) with BID or TID dosing frequency. The y-axis shows responder rate percentages from 0% to 60%. Bars show increasing responder rates with higher doses, some marked as statistically significant versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart depicting seizure reduction as median percent change from baseline versus dose (mg/day). It compares four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The chart shows increasing seizure reduction with higher doses, annotated with significant p-values for the data points, and notes placebo dose as zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin doses of 300 mg, 450 mg, and 800 mg daily against placebo, illustrating their relative effectiveness in improving pain over a range of improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis represents the percent of subjects without LTR, and the x-axis shows time in days. The Pregabalin group shows a higher percentage over time compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 between Pregabalin and placebo groups. The x-axis represents percent improvement, ranging from 0 to 100, while the y-axis shows percent of subjects improved. Two lines differentiate Pregabalin (solid) and placebo (dashed), with Pregabalin showing consistently higher improvement rates.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved from baseline to week 16 using BOCF, with two lines representing Pregabalin and Placebo. The y-axis shows percent of subjects improved, and the x-axis indicates percent improvement from 0 to 100%. The solid line corresponds to Pregabalin and the dotted line corresponds to Placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and adjusted by a factor of 0.85 for female patients. The equation is presented in a fraction format to aid clinical calculations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin, showing its molecular arrangement with labeled functional groups including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.